E
Elizabeth A. Shuster
Researcher at Mayo Clinic
Publications - 27
Citations - 3026
Elizabeth A. Shuster is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Neuromyelitis optica & Hereditary diffuse leukoencephalopathy with spheroids. The author has an hindex of 21, co-authored 27 publications receiving 2724 citations.
Papers
More filters
Journal ArticleDOI
Mutations in the colony stimulating factor 1 receptor ( CSF1R ) gene cause hereditary diffuse leukoencephalopathy with spheroids
Rosa Rademakers,Matt Baker,Alexandra M. Nicholson,Nicola J. Rutherford,Nicole A. Finch,Alexandra I. Soto-Ortolaza,Jennifer Lash,Christian Wider,Christian Wider,Aleksandra Wojtas,Mariely DeJesus-Hernandez,Jennifer Adamson,Naomi Kouri,Christina Sundal,Christina Sundal,Elizabeth A. Shuster,Jan O. Aasly,James MacKenzie,Sigrun Roeber,Hans A. Kretzschmar,Bradley F. Boeve,David S. Knopman,Ronald C. Petersen,Nigel J. Cairns,Bernardino Ghetti,Salvatore Spina,James Y. Garbern,Alexandros Tselis,Ryan J. Uitti,Pritam Das,Jay A. van Gerpen,James F. Meschia,Shawn Levy,Daniel F. Broderick,Neill R. Graff-Radford,Owen A. Ross,Bradley Miller,Russell H. Swerdlow,Dennis W. Dickson,Zbigniew K. Wszolek +39 more
TL;DR: It is suggested that HDLS may result from partial loss of CSF1R function, and an important role for microglial dysfunction in HDLS pathogenesis is suggested.
Journal ArticleDOI
Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial
Jerry S. Wolinsky,Ponnada A. Narayana,Paul O'Connor,P. K. Coyle,Corey C. Ford,Kenneth P. Johnson,Kenneth P. Johnson,Aaron Miller,Aaron Miller,Lillian Pardo,Shaul Kadosh,David Ladkani,Lorne F. Kastrukoff,Pierre Duquette,Mark S. Freedman,Marc Debouverie,Catherine Lubetski,Gilles Edan,E Roullet,Christian Confavreux,Alan J. Thompson,L D Blumhardt,L D Blumhardt,Stanley Hawkins,Thomas F. Scott,Daniel Wynn,Joanna Cooper,Stephen Thurston,Stanton B. Elias,Clyde E. Markowitz,David Mattson,John H. Noseworthy,Elizabeth A. Shuster,Jonathan L. Carter,Fred D. Lublin,WH Stuart,Michael D. Kaufman,Gary Birnbaum,Kottil Rammohan,Ruth H. Whitham,Cornelia Mihai,Steven J. Greenberg,Craig M. Smith,Mark A. Agius,Stan Van Den Noort,Lawrence W. Myers,James G. Nelson,Douglas S. Goodin,Barry G. W. Arnason,Khurram Bashir,Sharon G. Lynch,Patricia K. Coyle,Stephen Kamin,William A. Sheremata,Galen Mitchell,Andrew D. Goodman,Norman J Kachuck,Peter B. Dunne,J. William Lindsey,Elliot M. Frohman,James D. Bowen,Benjamin Rix Brooks,John W. Rose,Harold L. Moses,Douglas Jeffrey,Anne H. Cross,Robert P. Lisak,Timothy Vollmer,Jack P. Antel,Gary Cutter,Luanne M. Metz,Henry F. McFarland,Steven Reingold,Fred D. Lublin,Irina Vainrub,Lucie Lambert,Fengwei Zhong,Jeff Rasmituth,Saria Momin,Rivka Kreitman,Galia Shifroni,Irit Pinchasi,Yafit Stark +82 more
TL;DR: To determine whether glatiramer acetate slows accumulation of disability in primary progressive multiple sclerosis, a new drug is developed that acts as a ‘spatially aggregating agent’ to reduce the risk of disease progression.
Journal ArticleDOI
Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS)
Sean J. Pittock,Jan Debruyne,Karl N. Krecke,Caterina Giannini,Jelle van den Ameele,Veerle De Herdt,Andrew McKeon,Robert D. Fealey,Brian G. Weinshenker,Allen J. Aksamit,Bruce R. Krueger,Elizabeth A. Shuster,B. Mark Keegan +12 more
TL;DR: Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids is a definable, chronic inflammatory central nervous system disorder amenable to immunosuppressive treatment.
Journal ArticleDOI
Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients.
Anu Jacob,Marcelo Matiello,Brian G. Weinshenker,Dean M. Wingerchuk,Claudia F. Lucchinetti,Elizabeth A. Shuster,Jonathan L. Carter,B. Mark Keegan,Orhun H. Kantarci,Sean J. Pittock +9 more
TL;DR: Mycophenolate is associated with reduction in relapse frequency and stable or reduced disability in patients with NMO spectrum disorders, and it is concluded that attack prevention with immunosuppressive therapy is the mainstay of preventing disability.
Journal ArticleDOI
Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica
Yujuan Jiao,James P. Fryer,Vanda A. Lennon,Sarah M. Jenkins,Amy M. L. Quek,Carin Y. Smith,Andrew McKeon,Chiara Costanzi,Raffaele Iorio,Brian G. Weinshenker,Dean M. Wingerchuk,Elizabeth A. Shuster,Claudia F. Lucchinetti,Sean J. Pittock +13 more
TL;DR: AQP4-IgG–seronegative NMO is less frequent than previously reported and is clinically similar to AQP4–immunoglobulin G–seropositive NMO, and serological tests using recombinant AQP3 antigen are significantly more sensitive than tissue-based IIF for detecting AQP 4-IGG.